6-K: Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial
6-K: Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial
6-K：在Tropion-breast01 III期試驗中，Datopotamab Deruxtecan報告了轉移性HR陽性、HER2低或陰性乳腺癌患者的最終總存活率結果
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間